QC
TARS icon

Quadrature Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Quadrature Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Buy
+4,880
New +$312K ﹤0.01% 1192
2025
Q3 		– Sell
-14,500
Closed -$588K – 1474
2025
Q2 		$588K Buy
+14,500
New +$653K 0.01% 528

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Quadrature Capital's TARS Position: Q2 2026 in Review

Quadrature Capital opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 4,880 shares worth $307K. The stake represents ﹤0.01% of the portfolio and ranks #1192 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in TARS as recently as Q2 2025.

Quadrature Capital first reported a position in TARS in Q2 2025 and has held it in 2 quarters since. The position peaked at $588K in Q2 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Quadrature Capital held 4,880 shares of Tarsus Pharmaceuticals worth $307K as of Q2 2026.
  • Tarsus Pharmaceuticals was a new Quadrature Capital position in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1192 holding.
  • Quadrature Capital first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Tarsus Pharmaceuticals position peaked at $588K in Q2 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.